A new study sparks a war of words over the drug industry’s commitment to research
Both drug pricing reform advocates and drug makers are highlighting a statistic that shows the industry spends roughly $1 in $5 of revenues on research and development.
A version of this story first appeared in D.C. Diagnosis, STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.
WASHINGTON — A coalition of the drug industry’s fiercest foes is accusing the world’s top drug makers of hiding behind research and development “as an excuse for price-gouging American patients.” And they’re pointing to a new study that finds drug makers spent about 22% of their revenues on research and development
